Not a good buy right now: trend is still bearish (SMA_200 > SMA_20 > SMA_5) and momentum remains negative (MACD histogram below 0 and worsening).
Price is only slightly above key support (S1 ~0.948 vs current ~0.9628), so downside risk is immediate if support breaks; upside levels are stacked above (pivot ~1.107, R1 ~1.265).
Intellectia signals provide no “must-buy” trigger today (no AI Stock Picker / no SwingMax), so there’s no strong tactical edge for an impatient entry.
Financials show worsening losses (net income and EPS deterioration YoY), which weakens the fundamental backdrop despite a positive partnership headline.
Technical Analysis
Trend: Bearish structure with moving averages aligned down (SMA_200 > SMA_20 > SMA_5).
Momentum: MACD histogram -0.00489, below zero and negatively expanding → bearish momentum strengthening.
RSI: RSI_6 at 33.564 (weak/near-oversold but not a confirmed reversal signal).
Levels: Support S1 0.948 (nearby), then S2 0.85; Resistance pivot 1.107, then R1 1.265, R2 1.363.
Pattern-based forward view: 60% chance of -0.48% next day, -0.84% next week, +2.14% next month (near-term bias negative).
Event-driven: Partnership with Southern Energy and Frontline BioEnergy to develop a biomass-to-fuels platform in Louisiana.
Funding/support: Southern providing up to $2.05M for essential project components (helpful for execution/credibility).
Neutral/Negative Catalysts
Profitability deterioration: net loss and EPS worsened significantly YoY, which can pressure sentiment and financing expectations.
Financial Performance
Latest quarter: 2026/Q1.
Revenue: 1100 (reported as up 0.00% YoY) → essentially flat/unchanged growth.
Net income: -521,546 (down -87.14% YoY) → losses widened materially.
EPS: -0.14 (down -90.54% YoY) → per-share loss worsened.
Gross margin: -71.27 (reported as up 0.00% YoY) → margin remains negative/weak in absolute terms.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
No analyst rating/price target data provided; no visible recent upgrades/downgrades or target revisions in the dataset.
Wall Street-style pros: partnership/funding headline can improve near-term narrative and project validation.
Wall Street-style cons: worsening YoY losses/EPS and a clearly bearish technical trend make it hard to justify a fresh buy right now.
Wall Street analysts forecast DEVS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DEVS is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Analyst Rating
0
Wall Street analysts forecast DEVS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DEVS is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
